Trades on 4 secondary markets

Delfi Diagnostics

DELFI Diagnostics is a precision oncology company, founded in 2019 and built on research from the Johns Hopkins Kimmel Cancer Center, that combines machine learning with genome-wide analysis of cell-free DNA fragmentation patterns (an approach it calls DNA fragmentomics, or "fragmentomes") to develo

emerging 15.0 / 100 0 APIs View provider profile →

Company Diagnostics Precision Oncology Liquid Biopsy Cancer Screening Genomics

Delfi Diagnostics is an API provider whose private shares are listed on 4 secondary markets: Forge Global, Hiive, EquityZen, Nasdaq Private Market.

Where It Trades

F Forge Global View listing → H Hiive View listing → EZ EquityZen View listing → N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.